The current status of anti-GPCR drugs against different cancers / 药物分析学报
Journal of Pharmaceutical Analysis
;
(6): 517-521, 2020.
Artículo
en Chino
| WPRIM
| ID: wpr-883483
ABSTRACT
G protein coupled receptors (GPCRs) have emerged as the most potential target for a number of drug discovery programs ranging from control of blood pressure, diabetes, cure for genetic diseases to treatment of cancer. A panel of different ligands including hormones, peptides, ions and small molecules is responsible for activation of these receptors. Molecular genetics has identified key GPCRs, whose mutations or altered expressions are linked with tumorgenicity. In this review, we discussed recent advances regarding the involvement of GPCRs in the development of cancers and approaches to manipulating the mechanism behind GPCRs involved tumor growth and metastasis to treat different types of human cancer. This review provides an insight into the current scenario of GPCR-targeted therapy, progress to date and the challenges in the development of anticancer drugs.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Journal of Pharmaceutical Analysis
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS